Acknowledgement and Consent for Disclosure of Potential Conflict(s) of Interest and Waivers under 18 U.S.C. §208(b)(3) and 21 U.S.C. 355(n)(4)

Maha Hussain,	ΝЛ	1 1
WALA DUSSAIL	11/1	
itiai ia i iaccaii i,		· • ·

Committee: Oncologic Drugs Advisory Committee

Meeting Date: May 9, 2007

I acknowledge that contingent upon public disclosure of the financial interests listed below, related to (1) New Drug Application Junovan (mifamurtide), formerly known as (L-MTP-PE, liposomal muramyl tripeptide phosphatidyl ethanolamine), sponsored by IDM Pharma, Inc., for treatment of high-grade resectable non-metastatic osteosarcoma in combination with adjuvant chemotherapy for osteosarcoma. Genzyme Corporation, NOF Corporation, Ben Venue Laboratories, owned by Boehringer Ingelheim Corporation, the U.S. affiliate of Boehringer Ingelheim GmbH, and Solvias AG are the contract manufacturers of the liposomal formulation of muramyl tripeptide phosphatidylethanolamine; and, (2) New Drug Application orBec (oral beclamethasone dipropionate, BDP) tablets, sponsored by DOR BioPharma, Inc., for treatment of graft versus host disease (GVHD) involving the gastrointestinal tract in conjunction with an induction course of high-dose prednisone or prednisolone. I am eligible to receive waivers under 18 U.S.C. §208 (b)(3) and 21 U.S.C. 355(n)(4).

Type of Interest	Nature	Magnitude
Stock	Sponsor of issue 1	Worth from \$5,001 to \$25,000.
Stock	4 competing firms for issue 1; 2 competing firms for issue 2;	Worth from \$5,001 to \$25,000 per firm.

I hereby request that FDA make this information publicly available on my behalf. I understand that without public disclosure of these interests the waivers are not valid.

/s/	4/24/07	
Signature of SGE	Date	